Agios Pharmaceuticals (STU:8AP) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8AP Agios Pharmaceuticals Inc STU:8AP
44 GF Score
Price €26.00
GF Value €85.50
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

STU:8AP
44GF Score
Agios Pharmaceuticals Inc STU:8AP
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (STU:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €26.00 is trading 69.6% below its estimated GF Value™ of €85.50. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:8AP:

  • Total Noninterest Expense:
  • GF Value™: €85.50 vs. price of €26.00 (69.6% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the STU:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for STU:8AP

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.00
Price
€85.50
GF Value